The purpose of this research is to evaluate blood samples from HIV infected and non-HIV infected people opioid and non opioid users to understand how opioid affect the immune responses (body defenses against infection) to the flu vaccine.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
400
0.5 ml prefilled syringe administrated intramuscularly
University of Miami
Miami, Florida, United States
Change in the antibody response
Antibody response as measured by the serum vaccine antigen specific hemagglutination inhibition antibody levels.
Time frame: Baseline, 4 weeks, 6 months
Immune activation levels
Activation of T and B cells from peripheral blood mononuclear cells assessed via flow cytometry.
Time frame: Baseline
Inflammation biomarker levels
Plasma levels of Interleukin (IL)-6, IL-8, IL-12, IL-17, IL-22, Tumor necrosis factor (TNF) and monocyte activation markers soluble CD14 and soluble CD163 will be assessed via Magpix. All the biomarkers will be measured in nanograms/milliliter.
Time frame: Baseline
Circulating T follicular helper cell function
T follicular helper cell function measured from peripheral blood mononuclear cells via flow cytometry.
Time frame: Week 4
Circulating T follicular helper cell frequency
T follicular helper cell frequency measured from peripheral blood mononuclear cells via flow cytometry.
Time frame: Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.